AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02310633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Errorless Learning
Description: This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
Study NCT02310633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Retrieval Practice
Description: This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
Study NCT04317482 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard social stress task
Description: Participants will be asked to respond in detail to three scenarios. This is a standard social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
Study NCT04317482 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stressful experience in the ED
Description: Participants will be asked to imagine and then describe both feelings and bodily sensations experienced at their most stressful ED visit, in order to help them more fully re-experience the situation. In this regard, the second condition is more similar to stress imagery employed by Sinha et al, which elevated cortisol to a greater degree than a social stressor task. Participants may be prompted by an experimenter. However, the participant will receive no verbal nor nonverbal feedback.
Study NCT00595283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Child Interaction Therapy-Emotion Development (PCIT-ED)
Description: PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
Study NCT02911363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Captivator cassette
Description: The Captivator tissue cassette has an effect on the preservation of tissue histology.
Study NCT02911363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The specimen will be processed following the College of American Pathology Standards.
Study NCT03863444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal Preparation Education
Description: Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.
Study NCT03863444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
Study NCT03863444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
Study NCT01797029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIIL Live Attenuated Influenza Vaccine
Description: A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
Study NCT01797029 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
Study NCT01326598 — intervention group
Intervention type: DEVICE
Intervention: V-Go™
Description: Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
Study NCT02183467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356, low dose
Study NCT02183467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356, high dose
Study NCT02183467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02183467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT01753752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan- N- Acetylcysteine eye drops
Study NCT01753752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01707823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Given PO
Study NCT01707823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01144689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: 8 sessions of behavioral treatment for smoking cessation
Study NCT01144689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Therapy
Description: 8 sessions of behavioral treatment for smoking cessation
Study NCT00595283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental Education Parenting Intervention (DEPI)
Description: DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
Study NCT03713645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
Description: Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
Study NCT00333138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: FTY720 capsule was taken orally once a day
Study NCT00333138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1.25 mg capsule was given once daily
Study NCT01443143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Portion-controlled diet
Description: During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
Study NCT01443143 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Usual Diet
Description: During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study.
Study NCT04124822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Description: Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
Study NCT04124822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone 20 mg
Description: prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
Study NCT03528044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
Study NCT03729869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 200 mg of exogenous progesterone twice a day
Study NCT03729869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of matched placebo twice a day.
Study NCT00336193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visitation
Description: Home visitation to improve maternal health and well-being and parenting practices
Study NCT03444363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser group
Description: Laser application in addition to SRP
Study NCT03444363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Placebo laser application in addition to SRP
Study NCT03819283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Hepatic evaluation
Description: Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
Study NCT03260335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety management strategy
Description: Anxiety management strategy as per standard care plan
Study NCT03191396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
Study NCT03191396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
Study NCT02980835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
Study NCT02980835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
Study NCT02980835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
Study NCT02980835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
Study NCT02980835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
Study NCT02980835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
Study NCT02980835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
Study NCT02980835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
Study NCT01025245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil, MgSO4
Description: Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ \& Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
Study NCT02508701 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Message X Onsite/Offsite Vaccination
Description: Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
Study NCT00651118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00651118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine Hcl
Description: azelastine Hcl 548 mcg
Study NCT00651118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastineHcl / fluticasone propionate
Description: azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
Study NCT00651118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 200 mcg
Study NCT02974257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Thiamine 500mg IV twice daily for 2 days
Study NCT02974257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mL normal saline IV every 12 hours for 2 days
Study NCT03170336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
Study NCT03170336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
Study NCT03490669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-1
Description: humanized monoclonal antibody for intravenous administration
Study NCT02004054 — intervention group
Intervention type: OTHER
Intervention: measure of pupil diameter
Description: The measure will use infra-red cameras
Study NCT04608097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task intervention
Description: A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes.
Study NCT04608097 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo
Description: A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
Study NCT00815984 — intervention group
Intervention type: PROCEDURE
Intervention: measurements of lung function tests
Description: Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
Study NCT01801046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT01801046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01801046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo HMMACT with G-PBSC
Study NCT01801046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02517112 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02517112 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular parameters measurements
Description: with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
Study NCT02517112 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D-BCG sensor
Study NCT02074215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Aerobic exercises + dual task
Study NCT02074215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretch exercise
Description: Stretch exercise
Study NCT03227627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalStim
Description: One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
Study NCT03227627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
Study NCT00461565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Study NCT00461565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Study NCT00461565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY38-9456)
Description: B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Study NCT00461565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
Study NCT04355676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: 20 mg selinexor oral tablet.
Study NCT01951209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550mg orally twice daily for 12 weeks
Study NCT01951209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study NCT05642936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: didactic health education control
Description: didactic classroom-based comparison group that follows standard guidelines for diet, exercise and substance use with no stress reduction component
Study NCT05642936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation technique
Description: a mental technique derived from the Vedic tradition of ancient India and practiced by anyone for 20 minutes twice a day sitting